Tumor necrosis factor‐alpha inhibitors and acne fulminans: Friend or foe?

Acne fulminans (AF) is an uncommon variant of inflammatory acne with abrupt eruption of painful nodules, pustules, and hemorrhagic ulcerations, often associated with systemic symptoms. Paradoxical adverse reactions to tumor necrosis (TNF)‐alpha inhibitors have been reported, and rare cutaneous compl...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pediatric dermatology 2023-07, Vol.40 (4), p.678-680
Hauptverfasser: Barry, Kelly K., Neale, Holly D., Hawryluk, Elena B.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 680
container_issue 4
container_start_page 678
container_title Pediatric dermatology
container_volume 40
creator Barry, Kelly K.
Neale, Holly D.
Hawryluk, Elena B.
description Acne fulminans (AF) is an uncommon variant of inflammatory acne with abrupt eruption of painful nodules, pustules, and hemorrhagic ulcerations, often associated with systemic symptoms. Paradoxical adverse reactions to tumor necrosis (TNF)‐alpha inhibitors have been reported, and rare cutaneous complications include pyoderma gangrenosum, Sweet syndrome‐like hypersensitivity eruptions, and pustular folliculitis. We report an unusual case of AF in a patient with Crohn disease that worsened with doses of adalimumab, which is considered a second‐line treatment for AF. This case highlights that acneiform eruptions may be an underreported paradoxical adverse reaction to anti‐TNF alpha therapy.
doi_str_mv 10.1111/pde.15226
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2836334686</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2836334686</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3206-aa3580a81aef2cee57853b0a901589da723cdf94254a66863f5531032ee942f63</originalsourceid><addsrcrecordid>eNp1kMtKAzEUhoMotlYXvoAMuHIxbS6TTOpGpLYqFnRR1-F0JqEpc6lJB-nOR_AZfRIzTnXn2Rz4-fgO50fonOAhCTPa5HpIOKXiAPXD5jFJUnyI-jhlIpY4ET104v0aYyyFIMeoxwRPWSJkHz0tmrJ2UaUzV3vrIwPZtnZfH59QbFYQ2WpllzYkPoIqjyCrdGSaorQVVP46mjmrQxwEptY3p-jIQOH12X4P0Otsupg8xPPn-8fJ7TzOGMUiBmBcYpAEtKGZ1jyVnC0xjDHhcpxDSlmWm3FCeQJCSMEM54xgRrUOoRFsgC4778bVb432W7WuG1eFk4pKJlj7WUtddVT7mXfaqI2zJbidIli1talQm_qpLbAXe2OzLHX-R_72FIBRB7zbQu_-N6mXu2mn_AZ-cnYF</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2836334686</pqid></control><display><type>article</type><title>Tumor necrosis factor‐alpha inhibitors and acne fulminans: Friend or foe?</title><source>Wiley Online Library All Journals</source><creator>Barry, Kelly K. ; Neale, Holly D. ; Hawryluk, Elena B.</creator><creatorcontrib>Barry, Kelly K. ; Neale, Holly D. ; Hawryluk, Elena B.</creatorcontrib><description>Acne fulminans (AF) is an uncommon variant of inflammatory acne with abrupt eruption of painful nodules, pustules, and hemorrhagic ulcerations, often associated with systemic symptoms. Paradoxical adverse reactions to tumor necrosis (TNF)‐alpha inhibitors have been reported, and rare cutaneous complications include pyoderma gangrenosum, Sweet syndrome‐like hypersensitivity eruptions, and pustular folliculitis. We report an unusual case of AF in a patient with Crohn disease that worsened with doses of adalimumab, which is considered a second‐line treatment for AF. This case highlights that acneiform eruptions may be an underreported paradoxical adverse reaction to anti‐TNF alpha therapy.</description><identifier>ISSN: 0736-8046</identifier><identifier>EISSN: 1525-1470</identifier><identifier>DOI: 10.1111/pde.15226</identifier><identifier>PMID: 36573468</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Acne ; acne fulminans ; adalimumab ; adverse reaction ; Crohn disease ; Crohn's disease ; Eruptions ; Folliculitis ; Hemorrhage ; Inflammation ; Inflammatory bowel diseases ; Monoclonal antibodies ; paradoxical ; Pediatrics ; Pyoderma ; Pyoderma gangrenosum ; Side effects ; Skin eruptions ; Sweet's syndrome ; TNF‐alpha ; tofacitinib ; Tumor necrosis factor</subject><ispartof>Pediatric dermatology, 2023-07, Vol.40 (4), p.678-680</ispartof><rights>2022 Wiley Periodicals LLC.</rights><rights>2023 Wiley Periodicals LLC.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3206-aa3580a81aef2cee57853b0a901589da723cdf94254a66863f5531032ee942f63</citedby><cites>FETCH-LOGICAL-c3206-aa3580a81aef2cee57853b0a901589da723cdf94254a66863f5531032ee942f63</cites><orcidid>0000-0003-0382-4470 ; 0000-0003-0361-3657 ; 0000-0002-0862-3339</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fpde.15226$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fpde.15226$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36573468$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Barry, Kelly K.</creatorcontrib><creatorcontrib>Neale, Holly D.</creatorcontrib><creatorcontrib>Hawryluk, Elena B.</creatorcontrib><title>Tumor necrosis factor‐alpha inhibitors and acne fulminans: Friend or foe?</title><title>Pediatric dermatology</title><addtitle>Pediatr Dermatol</addtitle><description>Acne fulminans (AF) is an uncommon variant of inflammatory acne with abrupt eruption of painful nodules, pustules, and hemorrhagic ulcerations, often associated with systemic symptoms. Paradoxical adverse reactions to tumor necrosis (TNF)‐alpha inhibitors have been reported, and rare cutaneous complications include pyoderma gangrenosum, Sweet syndrome‐like hypersensitivity eruptions, and pustular folliculitis. We report an unusual case of AF in a patient with Crohn disease that worsened with doses of adalimumab, which is considered a second‐line treatment for AF. This case highlights that acneiform eruptions may be an underreported paradoxical adverse reaction to anti‐TNF alpha therapy.</description><subject>Acne</subject><subject>acne fulminans</subject><subject>adalimumab</subject><subject>adverse reaction</subject><subject>Crohn disease</subject><subject>Crohn's disease</subject><subject>Eruptions</subject><subject>Folliculitis</subject><subject>Hemorrhage</subject><subject>Inflammation</subject><subject>Inflammatory bowel diseases</subject><subject>Monoclonal antibodies</subject><subject>paradoxical</subject><subject>Pediatrics</subject><subject>Pyoderma</subject><subject>Pyoderma gangrenosum</subject><subject>Side effects</subject><subject>Skin eruptions</subject><subject>Sweet's syndrome</subject><subject>TNF‐alpha</subject><subject>tofacitinib</subject><subject>Tumor necrosis factor</subject><issn>0736-8046</issn><issn>1525-1470</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp1kMtKAzEUhoMotlYXvoAMuHIxbS6TTOpGpLYqFnRR1-F0JqEpc6lJB-nOR_AZfRIzTnXn2Rz4-fgO50fonOAhCTPa5HpIOKXiAPXD5jFJUnyI-jhlIpY4ET104v0aYyyFIMeoxwRPWSJkHz0tmrJ2UaUzV3vrIwPZtnZfH59QbFYQ2WpllzYkPoIqjyCrdGSaorQVVP46mjmrQxwEptY3p-jIQOH12X4P0Otsupg8xPPn-8fJ7TzOGMUiBmBcYpAEtKGZ1jyVnC0xjDHhcpxDSlmWm3FCeQJCSMEM54xgRrUOoRFsgC4778bVb432W7WuG1eFk4pKJlj7WUtddVT7mXfaqI2zJbidIli1talQm_qpLbAXe2OzLHX-R_72FIBRB7zbQu_-N6mXu2mn_AZ-cnYF</recordid><startdate>202307</startdate><enddate>202307</enddate><creator>Barry, Kelly K.</creator><creator>Neale, Holly D.</creator><creator>Hawryluk, Elena B.</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><orcidid>https://orcid.org/0000-0003-0382-4470</orcidid><orcidid>https://orcid.org/0000-0003-0361-3657</orcidid><orcidid>https://orcid.org/0000-0002-0862-3339</orcidid></search><sort><creationdate>202307</creationdate><title>Tumor necrosis factor‐alpha inhibitors and acne fulminans: Friend or foe?</title><author>Barry, Kelly K. ; Neale, Holly D. ; Hawryluk, Elena B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3206-aa3580a81aef2cee57853b0a901589da723cdf94254a66863f5531032ee942f63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Acne</topic><topic>acne fulminans</topic><topic>adalimumab</topic><topic>adverse reaction</topic><topic>Crohn disease</topic><topic>Crohn's disease</topic><topic>Eruptions</topic><topic>Folliculitis</topic><topic>Hemorrhage</topic><topic>Inflammation</topic><topic>Inflammatory bowel diseases</topic><topic>Monoclonal antibodies</topic><topic>paradoxical</topic><topic>Pediatrics</topic><topic>Pyoderma</topic><topic>Pyoderma gangrenosum</topic><topic>Side effects</topic><topic>Skin eruptions</topic><topic>Sweet's syndrome</topic><topic>TNF‐alpha</topic><topic>tofacitinib</topic><topic>Tumor necrosis factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Barry, Kelly K.</creatorcontrib><creatorcontrib>Neale, Holly D.</creatorcontrib><creatorcontrib>Hawryluk, Elena B.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><jtitle>Pediatric dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Barry, Kelly K.</au><au>Neale, Holly D.</au><au>Hawryluk, Elena B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tumor necrosis factor‐alpha inhibitors and acne fulminans: Friend or foe?</atitle><jtitle>Pediatric dermatology</jtitle><addtitle>Pediatr Dermatol</addtitle><date>2023-07</date><risdate>2023</risdate><volume>40</volume><issue>4</issue><spage>678</spage><epage>680</epage><pages>678-680</pages><issn>0736-8046</issn><eissn>1525-1470</eissn><abstract>Acne fulminans (AF) is an uncommon variant of inflammatory acne with abrupt eruption of painful nodules, pustules, and hemorrhagic ulcerations, often associated with systemic symptoms. Paradoxical adverse reactions to tumor necrosis (TNF)‐alpha inhibitors have been reported, and rare cutaneous complications include pyoderma gangrenosum, Sweet syndrome‐like hypersensitivity eruptions, and pustular folliculitis. We report an unusual case of AF in a patient with Crohn disease that worsened with doses of adalimumab, which is considered a second‐line treatment for AF. This case highlights that acneiform eruptions may be an underreported paradoxical adverse reaction to anti‐TNF alpha therapy.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>36573468</pmid><doi>10.1111/pde.15226</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0003-0382-4470</orcidid><orcidid>https://orcid.org/0000-0003-0361-3657</orcidid><orcidid>https://orcid.org/0000-0002-0862-3339</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0736-8046
ispartof Pediatric dermatology, 2023-07, Vol.40 (4), p.678-680
issn 0736-8046
1525-1470
language eng
recordid cdi_proquest_journals_2836334686
source Wiley Online Library All Journals
subjects Acne
acne fulminans
adalimumab
adverse reaction
Crohn disease
Crohn's disease
Eruptions
Folliculitis
Hemorrhage
Inflammation
Inflammatory bowel diseases
Monoclonal antibodies
paradoxical
Pediatrics
Pyoderma
Pyoderma gangrenosum
Side effects
Skin eruptions
Sweet's syndrome
TNF‐alpha
tofacitinib
Tumor necrosis factor
title Tumor necrosis factor‐alpha inhibitors and acne fulminans: Friend or foe?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T06%3A31%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tumor%20necrosis%20factor%E2%80%90alpha%20inhibitors%20and%20acne%20fulminans:%20Friend%20or%20foe?&rft.jtitle=Pediatric%20dermatology&rft.au=Barry,%20Kelly%20K.&rft.date=2023-07&rft.volume=40&rft.issue=4&rft.spage=678&rft.epage=680&rft.pages=678-680&rft.issn=0736-8046&rft.eissn=1525-1470&rft_id=info:doi/10.1111/pde.15226&rft_dat=%3Cproquest_cross%3E2836334686%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2836334686&rft_id=info:pmid/36573468&rfr_iscdi=true